Insmed Inc Quick Ratio (INSM) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Insmed Inc  (NASDAQ: INSM)

Insmed Inc's Quick Ratio

INSM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 2.37 below Insmed Inc's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 266 other companies have achieved higher Quick Ratio than Insmed Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1049 to 1140.

Explain Quick Ratio?
How much Cash & cash equivalents INSM´s has?
What are INSM´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

INSM Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 4.69 % 30.24 % 38.69 % 40.36 % -30.45 %
Y / Y Cash & cash equivalent Change -37.51 % 2.01 % -0.26 % 14.45 % 48.92 %
Quick Ratio MRQ 2.37 2.38 2.31 2.93 3.96
INSM's Total Ranking # 1140 # 1049 # 568 # 79 # 581
Seq. Current Liabilities Change -4.7 % -16.84 % 7.89 % 22.44 % 18.57 %
Seq. Cash & cash equivalent Change -5.17 % -14.44 % -14.88 % -9.52 % 54.8 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 267
Healthcare Sector # 456
Overall Market # 1140


Quick Ratio Statistics
High Average Low
32.96 7.86 1.04
(Dec 31 2010)   (Mar 31 2024)




Financial Statements
Insmed Inc's Current Liabilities $ 491 Millions Visit INSM's Balance sheet
Insmed Inc's Cash & cash equivalent $ 1,160 Millions Visit INSM's Balance sheet
Source of INSM's Sales Visit INSM's Sales by Geography


Cumulative Insmed Inc's Quick Ratio

INSM's Quick Ratio for the trailling 12 Months

INSM Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 27.87 % 13.1 % -2.04 % -7.56 % -12.76 %
Y / Y Cash & cash equivalent TTM Growth -7.79 % 15.75 % 29.97 % 50.82 % 74.77 %
Quick Ratio TTM 2.5 2.84 3 3.28 3.47
Total Ranking TTM # 3838 # 3795 # 1994 # 3039 # 2766
Seq. Current Liabilities TTM Growth 1.01 % 5.81 % 9.17 % 9.6 % -10.66 %
Seq. Cash & cash equivalent TTM Growth -11.25 % 0.39 % -0.06 % 3.56 % 11.41 %

Quick ratio ranking by company, industry and sector >> Back to INSM Financial Strength Comparisons >> Go to Compare INSM Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q2 2026 to $490.51 millions, cumulative Quick Ratio decreased to 2.5 below the Insmed Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 431 other companies have achieved higher Quick Ratio than Insmed Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3795 to 3838.

Explain Quick Ratio?
How much Cash & cash equivalents INSM´s has?
What are INSM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 432
Healthcare Sector # 883
Within the Market # 3838


trailing twelve months Quick Ratio Statistics
High Average Low
16.42 6.32 1.74
(Jun 30 2012)   (Jun 30 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Novelos Therapeutics, Inc.  6.49 $ 33.994  Millions$ 5.238  Millions
Genprex Inc   6.47 $ 15.154  Millions$ 2.342  Millions
Lisata Therapeutics Inc   6.45 $ 19.277  Millions$ 2.987  Millions
Larimar Therapeutics Inc   6.44 $ 219.880  Millions$ 34.166  Millions
United Therapeutics Corporation  6.13 $ 3,724.700  Millions$ 607.800  Millions
Serina Therapeutics Inc   6.12 $ 23.024  Millions$ 3.762  Millions
Revelation Biosciences Inc   6.11 $ 11.483  Millions$ 1.880  Millions
Spero Therapeutics Inc   6.02 $ 50.774  Millions$ 8.428  Millions
Aquestive Therapeutics Inc   5.98 $ 98.490  Millions$ 16.478  Millions
Xencor Inc  5.94 $ 486.350  Millions$ 81.865  Millions
Zymeworks Inc   5.73 $ 270.699  Millions$ 47.243  Millions
Tonix Pharmaceuticals Holding Corp   5.72 $ 176.232  Millions$ 30.785  Millions
Emmis Acquisition Corp   5.72 $ 0.708  Millions$ 0.124  Millions
Arcturus Therapeutics Holdings Inc   5.71 $ 191.483  Millions$ 33.536  Millions
Hoth Therapeutics Inc   5.70 $ 7.892  Millions$ 1.384  Millions
Silence Therapeutics Plc  5.67 $ 72.100  Millions$ 12.714  Millions
Adial Pharmaceuticals Inc   5.51 $ 28.200  Millions$ 5.121  Millions
Corbus Pharmaceuticals Holdings Inc   5.49 $ 117.941  Millions$ 21.483  Millions
Bio Green Med Solution Inc   5.48 $ 3.790  Millions$ 0.692  Millions
Arrowhead Pharmaceuticals Inc   5.47 $ 1,551.301  Millions$ 283.346  Millions
Context Therapeutics Inc   5.45 $ 42.990  Millions$ 7.885  Millions
Annexon Inc   5.44 $ 209.200  Millions$ 38.482  Millions
Mereo Biopharma Group Plc  5.37 $ 30.506  Millions$ 5.677  Millions
Cns Pharmaceuticals Inc   5.35 $ 19.985  Millions$ 3.738  Millions
Neurogene Inc   5.23 $ 112.485  Millions$ 21.505  Millions
Lexaria Bioscience Corp   5.20 $ 3.642  Millions$ 0.701  Millions
Barinthus Biotherapeutics Plc  5.19 $ 59.295  Millions$ 11.423  Millions
Immuneering Corporation  5.14 $ 41.731  Millions$ 8.116  Millions
Lyell Immunopharma Inc   5.12 $ 204.102  Millions$ 39.867  Millions
Altimmune inc   5.04 $ 63.008  Millions$ 12.501  Millions

Date modified: 2026-09-26T07:14:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.